| Ytd | 74.63% | |
| 1y | 172.62% |
| Open | 12.05 | Prev Close | 12.18 | Low | 11.85 | High | 12.20 | Mkt Cap | 1.17B |
| Vol | 814.17K | Avg Vol | 4.35M | EPS | -2.05 | P/E | -5.94 | Forward P/E | -12.57 |
| Beta | 2.47 | Short Ratio | 2.82 | Inst. Own | 72.45% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 12.27 | 200-d Avg | 8.03 | 1yr Est | 24.47 |
CMPS News
BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. R
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Ph
Compass Pathways (NASDAQ:CMPS)'s COMP360 treatment model may face fewer regulatory hurdles as new Ph
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring a
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotec
JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7
Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (N
CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease
Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support t
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Compass Pathways (NASDAQ:CMPS) wit
Evercore ISI Group analyst Gavin Clark-Gartner upgrades Compass Pathways (NASDAQ:CMPS) from In-Li
Stifel analyst Paul Matteis maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the pr
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and
Morgan Stanley analyst Judah Frommer reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight
Oppenheimer analyst Francois Brisebois reiterates Compass Pathways (NASDAQ:CMPS) with a Outperfor
BTIG analyst Thomas Shrader maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the pr
Compass Pathways plc (NASDAQ:CMPS) on Wednesday reported 26-week results from Part B of its Phase 3
Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression a
New 6-month data supports COMP360’s potential to establish a new standard of care in TRDData from po
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotec
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotec
Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial opera
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotec
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotec
COMPASS Pathways (CMPS) is positioned to pioneer COMP360, the first psychedelic drug for treatment-r
Compass Pathways NASDAQ: CMPS executives said the company remains on track to target a fourth-quarte
Liveramp Holdings Inc (NYSE: RAMP) rose in pre-market trading after being acquired by Publicis for $
Compass Pathways is nearing an inflection point, with solid Phase III data and government support po
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient acces
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotec
Health officials explored restricting specific antidepressants among SSRI drugs-sources
Top Wall Street analysts changed outlook on Adobe, AMD, Campbell's, Lineage, and WR Berkley. See
Analyst ratings for top stocks changed, including upgrades for FBP, CRWD, MSM.
https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/
Compass Pathways' stock surges after late-stage depression trial success.
